May 2025
1. TU ZL, Tu JF
   Cholelithiasis, Cholecystitis, and Choledocholithiasis.
   N Engl J Med. 2025;392:e42.
   

   >> Share

   
   May 2024
2. KOWDLEY KV, Levy C, Jones D
   Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
   N Engl J Med. 2024;390:1935-1936.
   

   >> Share

   
   
3. HIRSCHFIELD GM, Kremer AE, Levy C
   Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
   N Engl J Med. 2024;390:1934-1935.
   

   >> Share

   
   
4. IJICHI H
   Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:1934.
   

   >> Share

   
   
5. AREVALO-CANAS C, Arevalo-Serrano J
   Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:1933-1934.
   

   >> Share

   
   February 2024
6. SCHNABL B
   PPAR Agonists in Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:855-858.
   

   >> Share

   
   
7. HIRSCHFIELD GM, Bowlus CL, Mayo MJ, Kremer AE, et al
   A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:783-794.
   

   >> Share

   
   
8. ASSIS DN
   Advancing Second-Line Treatment for Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:853-854.
   

   >> Share

   
   November 2023
9. KOWDLEY KV, Bowlus CL, Levy C, Akarca US, et al
   Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
   N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185.
   

   >> Share

   
   August 2023
10. CHAVES JJ, Chaves-Chamorro JO
    Biliary Ascariasis.
    N Engl J Med. 2023;389:839.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share